Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.884
-0.002 (-0.26%)
Nov 5, 2024, 11:17 AM EST - Market open

Company Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.

The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.

Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio, Inc.
Gossamer Bio logo
Country United States
Founded 2015
IPO Date Feb 8, 2019
Industry Biotechnology
Sector Healthcare
Employees 135
CEO Faheem Hasnain

Contact Details

Address:
3013 Science Park Road, Suite 200
San Diego, California 92121
United States
Phone 858 684 1300
Website gossamerbio.com

Stock Details

Ticker Symbol GOSS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001728117
CUSIP Number 38341P102
ISIN Number US38341P1021
Employer ID 47-5461709
SIC Code 2834

Key Executives

Name Position
Faheem Hasnain Co-Founder, Chief Executive Officer, President and Chairman
Bryan Giraudo Chief Operating Officer and Chief Financial Officer
Robert P. Smith Chief Commercial Officer
Christian Waage Executive Vice President of Technical Operations and Administration
Jeff Boerneke General Counsel and Secretary
Deanna Weber Senior Vice President of Human Resources
Dr. Richard Aranda M.D. Chief Medical Officer
Caryn L. Peterson Executive Vice President of Regulatory Affairs
Matt Cravets Senior Vice President of Biometrics
Dr. Lisa Elizabeth Nolan Ph.D. MD and President of Gossamer Bio Ireland

Latest SEC Filings

Date Type Title
Sep 13, 2024 8-K Current Report
Aug 12, 2024 8-K Current Report
Aug 12, 2024 10-Q Quarterly Report
Aug 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jul 18, 2024 8-K Current Report
Jun 10, 2024 8-K Current Report
May 24, 2024 8-K Current Report
May 7, 2024 8-K Current Report
May 7, 2024 10-Q Quarterly Report
May 6, 2024 8-K Current Report